|

Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

RECRUITINGPhase 4Sponsored by Copenhagen Respiratory Research
Actively Recruiting
PhasePhase 4
SponsorCopenhagen Respiratory Research
Started2026-03-10
Est. completion2030-08-01
Eligibility
Age40 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06892210

Summary

The goal of this cluster randomized controlled trial is to determine the optimal treatment for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. The study compares the effects and side effects of hydrocortisone and prednisolone in patients above 40 years old diagnosed with chronic obstructive pulmonary disease with acute exacerbation. The main question is whether there is a difference in readmission for COPD excerbation or all cause mortality within thirty days. Participants will randomized to receive treatment with either hydrocortisone or prednisolone.

Eligibility

Age: 40 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥40 years
* Chronic obstructive pulmonary disease with acute exacerbation, unspecified: ICDJ44

Exclusion Criteria:

* All diagnoses that would merit treatment with a specific corticosteroid
* Pregnant or breastfeeding women
* Active tuberculosis or invasive fungal infection

Conditions2

COPDChronic Obstructive Pulmonary Disease (COPD)

Interventions2

HydrocortisoneMethylprednisolone (drug)

Browse More Trials

COPD trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.